ImmunoPrecise Antibodies (IPA) Earnings Date, Estimates & Call Transcripts $0.34 -0.06 (-14.54%) As of 10:21 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ImmunoPrecise Antibodies Latest Earnings SummaryLatest Q3 2025 Earnings DateMar. 28EstimatedActual EPS (Mar. 28) -$0.06 Consensus EPS (Mar. 28) -$0.06 ImmunoPrecise Antibodies posted Q3 2025 earnings on March 28, 2025, reporting an EPS of -$0.06, which hit analysts' consensus estimates of -$0.06. Quarterly revenue was reported to be $4.23 million, below the consensus estimate of $6.59 million. With a trailing EPS of -$1.16, ImmunoPrecise Antibodies' earnings are expected to grow next year, from ($0.27) to ($0.13) per share. Conference CallConference Call Transcript Get ImmunoPrecise Antibodies Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmunoPrecise Antibodies and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataIPA Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.IPA Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Remove Ads ImmunoPrecise Antibodies Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.09-$0.09-$0.09Q2 20251-$0.05-$0.05-$0.05Q3 20251-$0.06-$0.06-$0.06Q4 20251-$0.05-$0.05-$0.05FY 20254-$0.25-$0.25-$0.25Q1 20261-$0.06-$0.06-$0.06Q2 20261-$0.03-$0.03-$0.03Q3 20261-$0.02-$0.02-$0.02Q4 20261-$0.01-$0.01-$0.01FY 20264($0.12)($0.12)($0.12) Remove Ads ImmunoPrecise Antibodies Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails3/28/2025Q3 2025-$0.06-$0.06--$0.46$6.59M$4.23M12/10/2024Q2 2025-$0.05-$0.07 -$0.02-$0.07--9/16/2024Q1 2025-$0.09-$0.11 -$0.02-$0.11$4.96M$3.85M7/29/2024Q4 2024-$0.10-$0.52 -$0.42-$0.52$4.92M$4.76M3/14/2024Q3 2024-$0.08-$0.08--$0.08$4.43M$4.60M12/14/2023Q2 2024-$0.09-$0.07+$0.02-$0.07$4.44M$4.50M9/14/2023Q1 2024-$0.17-$0.11+$0.06-$0.11$3.98M$4.26M7/10/2023Q4 2023-$0.12-$0.15 -$0.03-$0.15$4.45M$4.15M ImmunoPrecise Antibodies Earnings - Frequently Asked Questions When did ImmunoPrecise Antibodies announce their last quarterly earnings? ImmunoPrecise Antibodies (NASDAQ:IPA) last announced its quarterly earning data on Friday, March 28, 2025. Learn more on IPA's earnings history. Did ImmunoPrecise Antibodies beat their earnings estimates last quarter? In the previous quarter, ImmunoPrecise Antibodies (NASDAQ:IPA) reported ($0.06) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.06). Learn more on analysts' earnings estimate vs. IPA's actual earnings. How can I listen to ImmunoPrecise Antibodies's earnings conference call? The conference call for ImmunoPrecise Antibodies's latest earnings report can be listened to online. Listen to Conference Call How can I read ImmunoPrecise Antibodies's conference call transcript? The conference call transcript for ImmunoPrecise Antibodies's latest earnings report can be read online. Read Transcript How much revenue does ImmunoPrecise Antibodies generate each year? ImmunoPrecise Antibodies (NASDAQ:IPA) has a recorded annual revenue of $24.07 million. How much profit does ImmunoPrecise Antibodies generate each year? ImmunoPrecise Antibodies (NASDAQ:IPA) has a recorded net income of -$20.13 million. IPA has generated -$1.16 earnings per share over the last four quarters. What is ImmunoPrecise Antibodies's EPS forecast for next year? ImmunoPrecise Antibodies's earnings are expected to grow from ($0.27) per share to ($0.13) per share in the next year. More Earnings Resources from MarketBeat Related Companies PDSB Earnings Results KRON Earnings Results VRPX Earnings Results XFOR Earnings Results CTOR Earnings Results VNRX Earnings Results AADI Earnings Results HOWL Earnings Results IMMX Earnings Results IPSC Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio? Remove Ads This page (NASDAQ:IPA) was last updated on 3/31/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoPrecise Antibodies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunoPrecise Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
